Mednet Logo

If you’re transitioning laterally between biologic classes due to adverse effects, do you repeat the loading dose?

For instance, if a patient develops conjunctivitis on IL 4/13 inhibitor (dupiliumab) to a IL13 (Adbry, Ebyglyss), or between IL13s? Similarly, this question pertains for 17s, and 23s.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Dermatology · Duke University
Answered on

I do usually repeat the loading dose when starting a new biologic, even if in the same class. If there is data on whether or not you should do this, I am not aware of it.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Dermatology · Solano Dermatology Associates
Answered on

It depends on how much psoriasis burden the patient has when making the switch. When the patient has been cleared or mostly cleared by the biologic currently about to be discontinued, I will go onto maintenance dose with the next. If the patient has not responded well to the current treatment to be ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Dermatology · Duke Health
Answered on

Agree--even within classes, there are differences in the MOA and specific targets (area of protein, etc). It would indeed be nice to have data!

Join for free or sign in to see the full answer